2024-09-11 - Analysis Report
## PFE Stock Analysis Report

**Company:** Pfizer Inc. is a multinational pharmaceutical corporation that develops and manufactures medicines and vaccines. 

**1. Performance vs S&P 500 (VOO):**

* PFE's cumulative return is -25.99%, significantly underperforming the S&P 500 (VOO) which has a cumulative return of 83.37%. 
* The relative divergence of -109.36 indicates PFE's performance has been lagging significantly behind the market. The relative divergence value suggests PFE is underperforming the market more than 90% of the time compared to its historical performance.

**2. Recent Price Movements:**

* Closing price: 29.41
* 5-day moving average: 28.63
* 20-day moving average: 28.75
* 60-day moving average: 28.84

The price is currently trading above all three moving averages, suggesting potential for continued upward movement.

**3. Technical Indicators:**

* **RSI (60.41):**  The RSI is above 50, indicating a bullish trend. However, it is not in overbought territory, suggesting there might be further room for upward movement.
* **PPO (0.11):** The PPO is positive, indicating a bullish signal. 
* **Delta_Previous_Relative_Divergence (-2.05):** The negative value indicates a slight short-term bearish trend. 
* **Expected_Return (0.0%):** The expected return is currently 0%, indicating potential for limited growth in the next 5 years based on current data.

**4. Recent Earnings and Outlook:**

| Date        | EPS   | Expected EPS |
|-------------|-------|--------------|
| 2024-07-30 | 0.60  | 0.458         |
| 2024-05-01 | 0.82  | 0.516         |
| 2024-01-30 | 0.10  | -0.19         |
| 2023-10-31 | -0.17 | -0.32         |
| 2023-08-01 | 0.67  | 0.56          |

* The most recent earnings report for Q2 2024 showed an EPS of 0.60, exceeding the expected EPS of 0.458. 
* This positive earnings surprise suggests the company is performing well, potentially driving future price appreciation.

**5. Overall Analysis:**

* PFE is currently underperforming the market significantly, but recent price action shows signs of bullish momentum.
* Positive technical indicators like the RSI and PPO suggest potential for upward movement.
* The recent earnings beat, exceeding expectations, provides a positive signal for future performance.
* However, the expected return is currently low, suggesting limited potential for significant growth in the near future.

**6. Conclusion:**

While PFE has lagged behind the market, recent price movements and positive technical indicators suggest a potential for a bullish trend. However, investors should remain cautious due to the low expected return and relatively high risk associated with the pharmaceutical industry. Further analysis is required to determine if PFE is a good investment opportunity. 
